Welcome to our dedicated page for P3 Health Partners news (Ticker: PIII), a resource for investors and traders seeking the latest updates and insights on P3 Health Partners stock.
P3 Health Partners Inc. (PIII) is a patient-centered, physician-led, and population health-focused healthcare company founded by Sherif Abdou and Amir Bacchus. The company is dedicated to transforming the way healthcare is delivered, with a mission to improve patient care, restore meaning to daily operations, and reinfuse care and health back into the healthcare system.
P3 operates with a unique model that aggregates and supports existing healthcare resources within the community to build an extensive network of providers. This network works collaboratively to deliver coordinated and integrated care to patients. The overarching goal is to improve patient outcomes, reduce healthcare costs, and enhance the overall experience for both patients and providers.
The team at P3 is composed of doctors, clinicians, and various support service professionals who share a deep passion for improving healthcare delivery. Recent achievements include significant growth in their provider network and successful partnerships that further their mission of delivering high-quality, cost-effective care.
Current projects at P3 include expanding their population health management services and implementing innovative care models that leverage data and technology to better serve their patient populations. Financially, P3 Health Partners Inc. continues to show robust performance, supported by its strong operational framework and strategic partnerships.
The company remains committed to its vision of transforming healthcare by working closely with physicians and healthcare providers to bring about meaningful changes in patient care delivery.
P3 Health Partners Inc. (NASDAQ: PIII), a physician-led population health management company, announced that Dr. Amir Bacchus, Co-founder and Chief Medical Officer, will participate in a fireside chat at the Jefferies Value-Based Care Summit in Miami Beach, FL on March 13, 2023, at 2:45 PM ET. Additionally, Dr. Bacchus will present at the Barclays Global Healthcare Conference on March 14, 2023, at 4:35 PM ET, with a live audio webcast available. P3 Health Partners is committed to improving healthcare outcomes through value-based care coordination, managing over 2,800 affiliated primary care providers across five states.
P3 Health Partners Inc. (NASDAQ: PIII) has announced that CEO Dr. Sherif Abdou will present at the TD Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, at 1:30 PM Eastern Time. The presentation will include insights into the company's patient-centered healthcare model and strategies for improving patient outcomes. A live audio webcast of the presentation will be available on P3’s website, along with a replay for 30 days post-event. P3 Health Partners focuses on population health management, collaborating with over 2,800 primary care providers across five states.
P3 Health Partners Inc. (NASDAQ: PIII) is participating in J.P. Morgan’s 41st Annual Healthcare Conference in San Francisco from January 9-12, 2023. The Company reaffirms its 2022 revenue guidance of $1.025 billion to $1.075 billion, reflecting a 61% to 69% increase from 2021. For 2023, P3 expects Medicare Advantage membership to grow to 115,000-120,000 and revenue between $1.20 billion and $1.25 billion. Adjusted EBITDA loss is forecasted at $40 million to $60 million, with expectations for positive Adjusted EBITDA in 2024.
P3 Health Partners Inc. (NASDAQ: PIII) will participate in J.P. Morgan’s 41st Annual Healthcare Conference in San Francisco from January 9-12, 2023. Dr. Sherif Abdou, the co-founder and CEO, is scheduled to present on January 11 at 5:15 pm Pacific Time. A live audio webcast of the presentation will be accessible here, with a replay available for 30 days on P3's investor relations webpage. P3 Health Partners focuses on population health management, serving over 100,000 patients with a network of 2,500 providers in five states.
P3 Health Partners Inc. (NASDAQ: PIII) announced the appointment of
P3 Health Partners reported a 59% revenue growth in Q3 2022, totaling $248.3 million, up from $156.2 million in Q3 2021. However, net loss increased to $65.3 million, compared to $32.1 million a year prior, primarily due to a $851.5 million goodwill impairment charge. Year-to-date revenue stands at $791.3 million, a 75% increase year-over-year. Adjusted EBITDA loss for the first nine months was $87.9 million, worse than the prior year's $59.9 million. Guidance for full-year Adjusted EBITDA loss has been revised to $118-$128 million.
P3 Health Partners Inc. (NASDAQ: PIII) will release its third-quarter financial results for the period ended
P3 Health Partners Inc. (NASDAQ: PIII) will participate in a "fireside chat" at the Credit Suisse 31st Annual Healthcare Conference on November 9 at 2:35 p.m. PST in Rancho Palos Verdes, California. The event will be streamed live, with a replay available on the company’s Investor Relations website. P3 Health, a physician-led population health management company, operates a network of over 2,600 primary care providers, managing care for over 100,000 patients across five states.
P3 Health Partners Inc. (NASDAQ: PIII) announced that it has received a Compliance Letter from the Nasdaq Hearing Panel on October 24, 2022, confirming that the company has cured its filing delinquency. This ensures P3 remains compliant with all applicable listing standards and allows its securities to continue trading on Nasdaq. The letter follows the company's filing of its Annual Report for the fiscal year ended December 31, 2021, and two Quarterly Reports, thereby making P3 current in its filing obligations with the U.S. Securities and Exchange Commission.
P3 Health Partners, Inc. (NASDAQ: PIII) reported a strong revenue growth of 84% in the first half of 2022, totaling $543 million. The at-risk Medicare Advantage membership surpassed 100,000 members. However, net loss increased significantly due to a $851.5 million goodwill impairment, raising PMPM net loss to $1,580. Adjusted EBITDA loss PMPM improved to $78.
The company raised its full-year 2022 revenue guidance to between $1.025 billion and $1.075 billion, driven by membership growth and partnerships.
FAQ
What is the current stock price of P3 Health Partners (PIII)?
What is the market cap of P3 Health Partners (PIII)?
What is P3 Health Partners Inc.?
Who founded P3 Health Partners?
What is the main mission of P3 Health Partners?
How does P3 Health Partners operate?
What recent achievements has P3 Health Partners made?
What current projects is P3 Health Partners involved in?
How does P3 Health Partners aim to improve patient outcomes?
What makes P3 Health Partners unique?
How can I stay updated on P3 Health Partners' news?
What is the financial condition of P3 Health Partners?
